Literature DB >> 19035593

Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies.

Anat Frydman-Marom1, Meirav Rechter, Irit Shefler, Yaron Bram, Deborah E Shalev, Ehud Gazit.   

Abstract

A rationally designed oligomerization inhibitor interacts with early intermediate assemblies of amyloid-beta polypeptide (Abeta) through the aromatic elements and inhibits their assembly into the toxic oligomers that cause Alzheimer's disease by a unique C(alpha)-methylation beta-breakage strategy. The electrostatic potential of the low-energy conformation of the dipeptide inhibitor bound to Abeta is shown.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19035593     DOI： 10.1002/anie.200802123

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


  30 in total

1.  Quantitative structure-activity relationship analysis of β-amyloid aggregation inhibitors.

Authors:  Shiri Stempler; Michal Levy-Sakin; Anat Frydman-Marom; Yaniv Amir; Roni Scherzer-Attali; Ludmila Buzhansky; Ehud Gazit; Hanoch Senderowitz
Journal:  J Comput Aided Mol Des       Date:  2010-12-17       Impact factor: 3.686

2.  Polymorphic triple beta-sheet structures contribute to amide hydrogen/deuterium (H/D) exchange protection in the Alzheimer amyloid beta42 peptide.

Authors:  Buyong Ma; Ruth Nussinov
Journal:  J Biol Chem       Date:  2011-08-05       Impact factor: 5.157

3.  Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.

Authors:  Susanne Aileen Funke; Thomas van Groen; Inga Kadish; Dirk Bartnik; Luitgard Nagel-Steger; Oleksandr Brener; Torsten Sehl; Renu Batra-Safferling; Christine Moriscot; Guy Schoehn; Anselm H C Horn; Andreas Müller-Schiffmann; Carsten Korth; Heinrich Sticht; Dieter Willbold
Journal:  ACS Chem Neurosci       Date:  2010-08-02       Impact factor: 4.418

4.  Oligomerization of FVFLM peptides and their ability to inhibit beta amyloid peptides aggregation: consideration as a possible model.

Authors:  M Kouza; A Banerji; A Kolinski; I A Buhimschi; A Kloczkowski
Journal:  Phys Chem Chem Phys       Date:  2017-01-25       Impact factor: 3.676

5.  Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease.

Authors:  Xueli Zhang; Yanli Tian; Zeng Li; Xiaoyu Tian; Hongbin Sun; Hong Liu; Anna Moore; Chongzhao Ran
Journal:  J Am Chem Soc       Date:  2013-10-25       Impact factor: 15.419

6.  Targeted studies on the interaction of nicotine and morin molecules with amyloid β-protein.

Authors:  Subramaniam Boopathi; Ponmalai Kolandaivel
Journal:  J Mol Model       Date:  2014-02-25       Impact factor: 1.810

7.  Binding Modes of Phthalocyanines to Amyloid β Peptide and Their Effects on Amyloid Fibril Formation.

Authors:  Ariel A Valiente-Gabioud; Dietmar Riedel; Tiago F Outeiro; Mauricio A Menacho-Márquez; Christian Griesinger; Claudio O Fernández
Journal:  Biophys J       Date:  2018-03-13       Impact factor: 4.033

8.  Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils.

Authors:  Mahiuddin Ahmed; Judianne Davis; Darryl Aucoin; Takeshi Sato; Shivani Ahuja; Saburo Aimoto; James I Elliott; William E Van Nostrand; Steven O Smith
Journal:  Nat Struct Mol Biol       Date:  2010-04-11       Impact factor: 15.369

9.  Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor.

Authors:  Roni Scherzer-Attali; Riccardo Pellarin; Marino Convertino; Anat Frydman-Marom; Nirit Egoz-Matia; Sivan Peled; Michal Levy-Sakin; Deborah E Shalev; Amedeo Caflisch; Ehud Gazit; Daniel Segal
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

10.  Structural and mechanistic basis behind the inhibitory interaction of PcTS on alpha-synuclein amyloid fibril formation.

Authors:  Gonzalo R Lamberto; Andrés Binolfi; María L Orcellet; Carlos W Bertoncini; Markus Zweckstetter; Christian Griesinger; Claudio O Fernández
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-30       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.